About CytoSite Bio
CytoSite Bio is a company based in United States founded in 2016 by Benjamin Larimer, Jim Jenson, Umar Mahmood, and Eric Wehrengerg Klee.. CytoSite Bio has raised $7.49 million across 4 funding rounds from investors including HHS. CytoSite Bio offers products and services including Granzyme B PET Agent and PET Imaging Protocol. CytoSite Bio operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others.
- Headquarter United States
- Founders Benjamin Larimer, Jim Jenson, Umar Mahmood, Eric Wehrengerg Klee
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.49 M (USD)
in 4 rounds
-
Latest Funding Round
$3.05 M (USD), Series A
Sep 24, 2020
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CytoSite Bio
CytoSite Bio offers a comprehensive portfolio of products and services, including Granzyme B PET Agent and PET Imaging Protocol. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
PET agent for detecting immune cell activation in cancer immunotherapy monitoring.
Protocol for non-invasive immune response evaluation in clinical trials.
Funding Insights of CytoSite Bio
CytoSite Bio has successfully raised a total of $7.49M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $3.05 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $3.0M
-
First Round
First Round
(18 Dec 2017)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Series A - CytoSite Bio | Valuation |
investors |
|
| Sep, 2018 | Amount | Grant - CytoSite Bio | Valuation |
investors |
|
| Aug, 2018 | Amount | Series A - CytoSite Bio | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CytoSite Bio
CytoSite Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CytoSite Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CytoSite Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cytosite Bio Comparisons
Competitors of CytoSite Bio
CytoSite Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cytosite Bio
Frequently Asked Questions about CytoSite Bio
When was CytoSite Bio founded?
CytoSite Bio was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is CytoSite Bio located?
CytoSite Bio is headquartered in United States.
Who is the current CEO of CytoSite Bio?
Jim Jenson is the current CEO of CytoSite Bio. They have also founded this company.
Is CytoSite Bio a funded company?
CytoSite Bio is a funded company, having raised a total of $7.49M across 4 funding rounds to date. The company's 1st funding round was a Series A of $4.42M, raised on Dec 18, 2017.
What does CytoSite Bio do?
CytoSite Bio was founded in 2016 in the United States and operates in the biotechnology sector focused on immuno-oncology. Precision imaging products are developed to detect active T-cell or NK cell activity through Granzyme B, which targets tumor cell killing by the immune system. These tools enable optimization of patient immunotherapy regimens by providing insights into treatment efficacy. The companys operations center on advancing diagnostic technologies for clinical use.
Who are the top competitors of CytoSite Bio?
CytoSite Bio's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
What products or services does CytoSite Bio offer?
CytoSite Bio offers Granzyme B PET Agent and PET Imaging Protocol.
Who are CytoSite Bio's investors?
CytoSite Bio has 1 investor. Key investors include HHS.